[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"e4c18b05-2e33-449c-8b23-428803a321f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03239145","created_at":"2021-01-18T16:00:23.405Z","updated_at":"2025-02-25T16:06:38.668Z","phase":"Phase 1","brief_title":"Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT03239145","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • trebananib (AMG 386)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/31/2017","start_date":" 08/31/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-20"},{"id":"4b8ceee7-908a-4445-958c-c977257ae44f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00807859","created_at":"2021-01-18T03:04:10.693Z","updated_at":"2024-07-02T16:36:00.698Z","phase":"Phase 1","brief_title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00807859","lead_sponsor":"Amgen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • capecitabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 02/27/2014","primary_completion_date":" 02/27/2014","study_txt":" Completion: 10/19/2015","study_completion_date":" 10/19/2015","last_update_posted":"2022-11-08"},{"id":"6b88056b-740c-4793-8c44-c7eb87101b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01555268","created_at":"2021-01-18T06:35:03.601Z","updated_at":"2024-07-02T16:36:04.006Z","phase":"Phase 1","brief_title":"Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT01555268","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" VEGFA • CD34","pipe":" | ","alterations":" VEGFA expression","tags":["VEGFA • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2011","start_date":" 10/31/2011","primary_txt":" Primary completion: 09/24/2013","primary_completion_date":" 09/24/2013","study_txt":" Completion: 08/03/2016","study_completion_date":" 08/03/2016","last_update_posted":"2022-09-13"},{"id":"9fbad8bb-68c1-4851-a2df-5eb9ae9738a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00479817","created_at":"2021-01-18T01:42:50.375Z","updated_at":"2024-07-02T16:36:52.301Z","phase":"Phase 2","brief_title":"Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00479817","lead_sponsor":"Amgen","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 161","initiation":"Initiation: 07/05/2007","start_date":" 07/05/2007","primary_txt":" Primary completion: 08/11/2009","primary_completion_date":" 08/11/2009","study_txt":" Completion: 12/09/2019","study_completion_date":" 12/09/2019","last_update_posted":"2019-12-18"},{"id":"38df0960-76c7-4187-a0c3-d963dabfc05c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01538095","created_at":"2021-01-18T06:29:49.779Z","updated_at":"2024-07-02T16:37:28.722Z","phase":"Phase 1","brief_title":"Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors","source_id_and_acronym":"NCT01538095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2016-10-03"}]